Goldline Pharmaceutical Ltd.BSE: GLPL

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

· Issued by Goldline Pharmaceutical Ltd. via BSE India

Filed with BSE · · 9 pages · English

Summary by 6ix AI

The filing states that Mr. Amol Laxmikant Mujumdar, the Promoter and Managing Director, acquired a specific number of equity shares through the open market. This acquisition represents a small percentage of the total issued and paid-up share capital of the company. The document requests the BSE to record this disclosure accordingly.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Goldline Pharmaceutical Ltd. on 6ix

Earlier from Goldline Pharmaceutical

Later from Goldline Pharmaceutical

All Goldline Pharmaceutical news releases